{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T04:48:27Z","timestamp":1788497307718,"version":"build-2803163510"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001804","name":"Canada Research Chairs","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001804","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.neuropharm.2025.110436","type":"journal-article","created":{"date-parts":[[2025,3,30]],"date-time":"2025-03-30T21:56:26Z","timestamp":1743371786000},"page":"110436","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Fatty acid amide hydrolase in comorbid borderline personality disorder and major depressive disorder: Imaging with [11C]CURB PET"],"prefix":"10.1016","volume":"273","author":[{"given":"Michelle A.","family":"De Pol","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorsa","family":"Rafiei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey H.","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly L.","family":"Desmond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shelley","family":"McMain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Boileau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7515-558X","authenticated-orcid":false,"given":"Jerry","family":"Warsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0075-2918","authenticated-orcid":false,"given":"Pablo","family":"Rusjan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Schmahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2087-5125","authenticated-orcid":false,"given":"Neil","family":"Vasdev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren R.","family":"Gray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Aloysius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan J.","family":"Kolla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2025.110436_bib1","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/sltb.12059","article-title":"Suicide attempts in major depressed patients with personality disorder","volume":"44","author":"Amore","year":"2014","journal-title":"Suicide Life-Threatening Behav."},{"key":"10.1016\/j.neuropharm.2025.110436_bib2","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.tics.2004.02.010","article-title":"Inhibition and the right inferior frontal cortex","volume":"8","author":"Aron","year":"2004","journal-title":"Trends Cognit. Sci."},{"key":"10.1016\/j.neuropharm.2025.110436_bib3","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1038\/npp.2010.80","article-title":"Genetic deletion of fatty acid amide hydrolase alters emotional behavior and serotonergic transmission in the dorsal raphe, prefrontal cortex, and hippocampus","volume":"35","author":"Bambico","year":"2010","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2025.110436_bib4","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0140635","article-title":"Overcoming barriers to skills training in borderline personality disorder: a qualitative interview study","volume":"10","author":"Barnicot","year":"2015","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110436_bib5","article-title":"Comorbidities in borderline personality disorder","volume":"30","author":"Biskin","year":"2013","journal-title":"Psychiatr. Times"},{"issue":"9","key":"10.1016\/j.neuropharm.2025.110436_bib6","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.biopsych.2016.04.012","article-title":"Fatty acid amide hydrolase binding in brain of cannabis users: imaging with the novel radiotracer [11C] CURB","volume":"80","author":"Boileau","year":"2016","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2025.110436_bib7","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1038\/jcbfm.2015.133","article-title":"Blocking of fatty acid amide hydrolase activity with PF-04457845 in human brain: a positron emission tomography study with the novel radioligand [11C] CURB","volume":"35","author":"Boileau","year":"2015","journal-title":"J. Cerebr. Blood Flow Metabol."},{"key":"10.1016\/j.neuropharm.2025.110436_bib8","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1038\/jcbfm.2015.119","article-title":"The fatty acid amide hydrolase C385A variant affects brain binding of the positron emission tomography tracer [11C] CURB","volume":"35","author":"Boileau","year":"2015","journal-title":"J. Cerebr. Blood Flow Metabol."},{"key":"10.1016\/j.neuropharm.2025.110436_bib9","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1037\/h0046900","article-title":"An inventory for assessing different kinds of hostility","volume":"21","author":"Buss","year":"1957","journal-title":"J. Consult. Psychol."},{"key":"10.1016\/j.neuropharm.2025.110436_bib10","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.jad.2020.11.111","article-title":"How does borderline personality disorder affect management and treatment response of patients with major depressive disorder? A comprehensive review","volume":"281","author":"Ceresa","year":"2021","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.neuropharm.2025.110436_bib11","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/j.jpsychires.2012.03.021","article-title":"Expression pattern of the cannabinoid receptor genes in the frontal cortex of mood disorder patients and mice selectively bred for high and low fear","volume":"46","author":"Choi","year":"2012","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.neuropharm.2025.110436_bib12","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1111\/add.15743","article-title":"Clinical management of cannabis withdrawal","volume":"117","author":"Connor","year":"2022","journal-title":"Addiction"},{"key":"10.1016\/j.neuropharm.2025.110436_bib13","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/BF00428707","article-title":"Effects of \u0394 9-Tetrahydrocannabinol on social behaviour in mice: comparison between two vehicles","volume":"47","author":"Dorr","year":"1976","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.neuropharm.2025.110436_bib14","first-page":"561","article-title":"Community and clinical epidemiology of borderline personality disorder","volume":"41","author":"Ellison","year":"2018","journal-title":"Psychiatr. Clin."},{"key":"10.1016\/j.neuropharm.2025.110436_bib15","series-title":"User's Guide for the SCID-5-PD (Structured Clinical Interview for DSM-5 Personality Disorder)","author":"First","year":"2015"},{"key":"10.1016\/j.neuropharm.2025.110436_bib16","series-title":"Structured Clinical Interview for DSM-5\u2014Research Version","author":"First","year":"2015"},{"key":"10.1016\/j.neuropharm.2025.110436_bib17","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.v69n0404","article-title":"Prevalence, correlates, disability, and comorbidity of DSM-IV borderline personality disorder: results from the wave 2 national epidemiologic survey on alcohol and related conditions","volume":"69","author":"Grant","year":"2008","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.neuropharm.2025.110436_bib18","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.08m04200gre","article-title":"Personality disorders predict relapse after remission from an episode of major depressive disorder: a 6-year prospective study","volume":"71","author":"Grilo","year":"2010","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.neuropharm.2025.110436_bib19","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1136\/jnnp.23.1.56","article-title":"A rating scale for depression","volume":"23","author":"Hamilton","year":"1960","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.neuropharm.2025.110436_bib20","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/sj.mp.4001376","article-title":"Upregulation of CB1 receptors and agonist-stimulated [35S] GTP\u03b3S binding in the prefrontal cortex of depressed suicide victims","volume":"9","author":"Hungund","year":"2004","journal-title":"Mol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2025.110436_bib21","first-page":"171","article-title":"Automated radiosynthesis of [18F] FMPEP-d2 for cannabinoid receptor PET imaging","volume":"13","author":"Jiang","year":"2023","journal-title":"American J Nuclear Med Molecular Imaging"},{"key":"10.1016\/j.neuropharm.2025.110436_bib22","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1017\/neu.2016.68","article-title":"A dual inhibitor of FAAH and TRPV1 channels shows dose-dependent effect on depression-like behaviour in rats","volume":"29","author":"Kirkedal","year":"2017","journal-title":"Acta Neuropsychiatr."},{"key":"10.1016\/j.neuropharm.2025.110436_bib23","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3389\/fnbeh.2018.00041","article-title":"The endocannabinoid system, aggression, and the violence of synthetic cannabinoid use, borderline personality disorder, antisocial personality disorder, and other psychiatric disorders","volume":"12","author":"Kolla","year":"2018","journal-title":"Front. Behav. Neurosci."},{"key":"10.1016\/j.neuropharm.2025.110436_bib24","doi-asserted-by":"crossref","DOI":"10.1038\/s41386-020-0731-y","article-title":"Elevated fatty acid amide hydrolase in the prefrontal cortex of borderline personality disorder: a [11C]CURB positron emission tomography study","volume":"45","author":"Kolla","year":"2020","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2025.110436_bib25","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/s41398-020-01144-2","article-title":"Lower amygdala fatty acid amide hydrolase in violent offenders with antisocial personality disorder: an [11C]CURB positron emission tomography study","volume":"11","author":"Kolla","year":"2021","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.neuropharm.2025.110436_bib26","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/j.euroneuro.2016.03.003","article-title":"Genetically reduced FAAH activity may be a risk for the development of anxiety and depression in persons with repetitive childhood trauma","volume":"26","author":"Lazary","year":"2016","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.neuropharm.2025.110436_bib27","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s00213-001-0946-5","article-title":"Involvement of CB1 cannabinoid receptors in emotional behaviour","volume":"159","author":"Martin","year":"2002","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.neuropharm.2025.110436_bib28","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1521\/pedi.2009.23.2.156","article-title":"Meta-analyses of mood stabilizers, antidepressants and antipsychotics in the treatment of borderline personality disorder: effectiveness for depression and anger symptoms","volume":"23","author":"Mercer","year":"2009","journal-title":"J. Pers. Disord."},{"key":"10.1016\/j.neuropharm.2025.110436_bib29","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1126\/science.415367","article-title":"\u03949-Tetrahydrocannabinol: antiaggressive effects in mice, rats, and squirrel monkeys","volume":"199","author":"Miczek","year":"1978","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2025.110436_bib30","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyg.2021.679904","article-title":"Decision making and impulsivity in young adult cannabis users","volume":"12","author":"O'Donnell","year":"2021","journal-title":"Front. Psychol."},{"key":"10.1016\/j.neuropharm.2025.110436_bib31","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1002\/1097-4679(199511)51:6<768::AID-JCLP2270510607>3.0.CO;2-1","article-title":"Factor structure of the Barratt impulsiveness scale","volume":"51","author":"Patton","year":"1995","journal-title":"J. Clin. Psychol."},{"key":"10.1016\/j.neuropharm.2025.110436_bib32","series-title":"Neurobiology and Physiology of the Endocannabinoid System","first-page":"35","article-title":"Physiology of the endocannabinoid system: imaging and the use of positron emission tomography (PET)","author":"Poluga","year":"2023"},{"key":"10.1016\/j.neuropharm.2025.110436_bib33","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.3390\/ijms22031047","article-title":"Elevated brain fatty acid amide hydrolase induces depressive-like phenotypes in rodent models: a review","volume":"22","author":"Rafiei","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.neuropharm.2025.110436_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.pbb.2023.173558","article-title":"A potential role of hippocampus on impulsivity and alcohol consumption through CB1R","volume":"225","author":"Romero-Torres","year":"2023","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2025.110436_bib35","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/jcbfm.2012.180","article-title":"Mapping human brain fatty acid amide hydrolase activity with PET","volume":"33","author":"Rusjan","year":"2013","journal-title":"J. Cerebr. Blood Flow Metabol."},{"key":"10.1016\/j.neuropharm.2025.110436_bib36","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/s00406-013-0470-8","article-title":"Fatty acid ethanolamide levels are altered in borderline personality and complex posttraumatic stress disorders","volume":"264","author":"Schaefer","year":"2014","journal-title":"Eur. Arch. Psychiatr. Clin. Neurosci."},{"key":"10.1016\/j.neuropharm.2025.110436_bib37","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1176\/appi.ajp.2010.10050695","article-title":"Relationship of personality disorders to the course of major depressive disorder in a nationally representative sample","volume":"168","author":"Skodol","year":"2011","journal-title":"Am. J. Psychiatr."},{"key":"10.1016\/j.neuropharm.2025.110436_bib38","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1521\/pedi.2006.20.4.307","article-title":"Heightened subjective experience of depression in borderline personality disorder","volume":"20","author":"Stanley","year":"2006","journal-title":"J. Pers. Disord."},{"key":"10.1016\/j.neuropharm.2025.110436_bib39","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S0091-3057(97)00422-X","article-title":"Biphasic effects of anandamide","volume":"59","author":"Sulcova","year":"1998","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2025.110436_bib40","first-page":"1","article-title":"First-in-human in vivo undefined imaging and quantification of monoacylglycerol lipase in the brain: a PET study with 18 FT-401","volume":"13","author":"Takahata","year":"2022","journal-title":"Eur. J. Nucl. Med. Mol. Imag."},{"key":"10.1016\/j.neuropharm.2025.110436_bib41","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1002\/da.23122","article-title":"Clinical traits of patients with major depressive disorder with comorbid borderline personality disorder based on propensity score matching","volume":"38","author":"Tong","year":"2021","journal-title":"Depress. Anxiety"},{"key":"10.1016\/j.neuropharm.2025.110436_bib42","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1021\/acschemneuro.0c00305","article-title":"Classics in neuroimaging: imaging the endocannabinoid pathway with PET","volume":"11","author":"Varlow","year":"2020","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.neuropharm.2025.110436_bib43","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.nucmedbio.2010.08.001","article-title":"[11C] CURB: evaluation of a novel radiotracer for imaging fatty acid amide hydrolase by positron emission tomography","volume":"38","author":"Wilson","year":"2011","journal-title":"Nucl. Med. Biol."},{"key":"10.1016\/j.neuropharm.2025.110436_bib44","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1521\/pedi.17.3.233.22147","article-title":"Zanarini rating scale for borderline personality disorder (ZAN-BPD): a continuous measure of DSM-IV borderline psychopathology","volume":"17","author":"Zanarini","year":"2003","journal-title":"J. Pers. Disord."},{"key":"10.1016\/j.neuropharm.2025.110436_bib45","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19030833","article-title":"Cannabinoid receptors and the endocannabinoid system: signaling and function in the central nervous system","volume":"19","author":"Zou","year":"2018","journal-title":"Int. J. Mol. Sci."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002839082500142X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002839082500142X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T08:32:43Z","timestamp":1778142763000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S002839082500142X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":45,"alternative-id":["S002839082500142X"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2025.110436","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Fatty acid amide hydrolase in comorbid borderline personality disorder and major depressive disorder: Imaging with [11C]CURB PET","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2025.110436","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"110436"}}